Literature DB >> 18297692

Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.

Nicola Simola1, Sandro Fenu, Pier G Baraldi, Mojgan Aghazadeh Tabrizi, Micaela Morelli.   

Abstract

We have recently demonstrated how antagonism of adenosine A(2A) receptors within the globus pallidus (GP) ipsilateral to dopaminergic denervation potentiates contralateral rotational behavior induced by the dopamine precursor L-DOPA in 6-hydroxydopamine-lesioned hemiparkinsonian rats. To further characterize the influence of pallidal A(2A) receptor blockade on the motor stimulant effects elicited by dopamine receptor activation, hemiparkinsonian rats were infused with the water-soluble A(2A) antagonist SCH BT2 in the GP, alone or in combination with systemic administration of either SKF 38393 or quinpirole, to stimulate dopamine D(1) or D(2) receptors, respectively. SCH BT2 alone (5 mug/1 mul) neither altered motor behavior nor produced postural asymmetry. In contrast, the contralateral rotations elicited by SKF 38393 (1.5 mg/kg) as well as quinpirole (0.05 mg/kg) were potentiated by the concomitant intrapallidal infusion of SCH BT2. The results of this study demonstrate that blockade of pallidal A(2A) receptors exerts a facilitatory influence on the motor effects produced by the selective stimulation of either D(1) or D(2) dopamine receptors in hemiparkinsonian rats and suggest an involvement of GP in the antiparkinsonian activity of A(2A) receptor antagonists. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297692     DOI: 10.1002/syn.20504

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

Review 1.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

2.  Medical management of Parkinson's disease: focus on neuroprotection.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Camilo Rios
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

3.  The Old and New Visions of Biased Agonism Through the Prism of Adenosine Receptor Signaling and Receptor/Receptor and Receptor/Protein Interactions.

Authors:  Rafael Franco; Rafael Rivas-Santisteban; Irene Reyes-Resina; Gemma Navarro
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

Review 4.  Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease.

Authors:  Emmanuelle Pourcher; Philippe Huot
Journal:  Mov Disord Clin Pract       Date:  2015-07-25

Review 5.  Natural Compounds as Guides for the Discovery of Drugs Targeting G-Protein-Coupled Receptors.

Authors:  Joan Serrano-Marín; Irene Reyes-Resina; Eva Martínez-Pinilla; Gemma Navarro; Rafael Franco
Journal:  Molecules       Date:  2020-10-30       Impact factor: 4.411

6.  Methamphetamine Blocks Adenosine A2A Receptor Activation via Sigma 1 and Cannabinoid CB1 Receptors.

Authors:  Mireia Casanovas; Irene Reyes-Resina; Alejandro Lillo; Jaume Lillo; Raul López-Arnau; Jorge Camarasa; Elena Escubedo; Gemma Navarro; Rafael Franco
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.